Home / Business and Economy / PTC Therapeutics Exec Sells $212K in Stock
PTC Therapeutics Exec Sells $212K in Stock
14 Jul
Summary
- Officer sold 2,464 shares valued at $90.25 each.
- Transaction occurred on July 9, 2026, under a trading plan.
- Company focuses on rare genetic disorder therapies.
On July 9, 2026, Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics, Inc., executed a sale of 2,464 common shares at $90.25 per share. This transaction was conducted as part of a pre-arranged Rule 10b5-1 trading plan, a strategy designed to manage equity compensation while preventing insider trading concerns. The shares originated from an option grant dated January 3, 2025.
Almstead's sale, valued at approximately $212,000, reflects a routine liquidity event. Post-transaction, he continues to hold a substantial interest in PTC Therapeutics, including 63,198 shares of common stock and 45,036 derivative awards. This ensures continued alignment with the company's performance and shareholder value.
PTC Therapeutics, a biopharmaceutical company, is actively developing therapies for rare genetic disorders. As of July 10, 2026, its market capitalization stood at $7.0 billion. The company reported trailing twelve-month revenue of $827.1 million, alongside a net loss of $186.7 million.
